MedTrace Logo

A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas

NCT00880581 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-03-14

Study results available
· View outcomes & findings →

Summary

To assess the feasibility of using intra-tumoral PF-3512676 in combination with local radiation as a therapy for lowgrade b-cell lymphoma.

Conditions

  • Lymphoma, Non-Hodgkin
  • Lymphoma
  • Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell
  • Lymphomas: Non-Hodgkin

Interventions

DRUG

PF-3512676

18 mg injection

RADIATION

Local radiotherapy

2 gray (2 Gy) on each of Days 1 and 2

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Ronald Levy

    lead OTHER

Principal Investigators

  • Ronald Levy · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-09-30
Completion
2015-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00880581 on ClinicalTrials.gov